Partnerships, research, product updates, and talks from the Human Chemical team.
Featured · Partnership · September 8, 2026
BMS nonclinical toxicology teams use our agents for impurities, metabolite liabilities, environmental fate, and other safety questions from discovery through development.
Product · October 5, 2026
A new series shows how our agents support expert review of (Q)SAR mutagenicity predictions for drug impurities.
In the news · September 30, 2026
PharmaVoice quotes Srijit Seal on AI agents in drug research, and BioPharma Dive also ran the article.
Partnership · September 2026
Over six months, Beiersdorf will use our agents to build an animal-free risk assessment workflow, with a joint case study planned for publication.
Partnership · September 2026
GDIT brings our platform to federal scientists working on new approach methodologies, and we presented at GDIT's Mission Tech Innovation Showcase.
Partnership · July 2026
Our agents help consortium scientists screen data sources, find data gaps, and support weight-of-evidence work for next-generation liver safety models.
Partnership · June 2026
Huntsman uses our agents for chemistry, toxicology, and regulatory assessments, which its VP of Global Innovation expects to speed new chemicals to market.
Partnership · April 2026
We are validating our automated implementation of the FDA Expanded Decision Tree with FDA scientists, and we will publish the results together.
The agreement does not imply endorsement by the U.S. Government or the FDA.
Talk · September 29 to 30, 2026
Srijit Seal joined the BioTechX roundtable on AI for drug discovery and presented agentic AI for target safety assessment at Discovery on Target.
Product · September 2026
Run all 254 models and 70 profilers at once for multiple chemicals, with no software to install.
Research · September 2026
Our agents ran the FDA Expanded Decision Tree to rank chlorobenzene derivatives for chronic oral hazard, and the abstract is in Toxicology Letters 423.
Research · September 2, 2026
Srijit Seal presented multi-agent AI for rapid medical device biocompatibility assessment in Minneapolis, where Human Chemical was also a sponsor.
Talk · August 2026
Mattson Thieme, Isaac Wilks, and Srijit Seal presented agentic AI for toxicology and pesticide safety assessment at the American Chemical Society Fall meeting.
Research · August 2026
Srijit Seal led a cross-industry preprint on validating machine learning models for small molecule drug discovery, with co-authors from more than a dozen companies.
Research · August 7, 2026
Srijit Seal co-authored a perspective on where AI has moved drug discovery forward, where its impact is still limited, and why.
Research · July 31, 2026
LIVER-Combine, a team that includes Srijit Seal, was one of 20 Phase 1 winners out of more than 160 teams in the NIH Common Fund's Complement-ARIE challenge on new approach methods for liver toxicity.
Talk · June 9, 2026
Srijit Seal, Principal Agentic AI Scientist at Human Chemical, showed how AI agents support chemical risk assessment. Watch the recording on YouTube.
Talk · May 8, 2026
We presented ICH M7 impurity case studies in the AI session of the Genetic Toxicology Association meeting, which Srijit Seal co-chaired.
Talk · January 16, 2026
Mattson Thieme and Isaac Wilks demonstrated agentic AI workflows for safer products in a training hosted by ASCCT and PCRM.
In the news · 2026
In "From chemist to AI agent builder," Srijit Seal talks about building AI agents for drug discovery.
These are the meetings where our team speaks next.
ASCCT 15th Annual Meeting, Durham, North Carolina
Srijit Seal and Isaac Wilks speak in the session on evaluating AI workflows in human health risk assessment.
SETAC North America 47th Annual Meeting, Montreal
Isaac Wilks gives a platform talk in the session on integrating AI and new approach methodologies for next-generation risk assessment.
American College of Toxicology 47th Annual Meeting, San Antonio
Srijit Seal co-chairs a course on agentic AI in toxicology where Mattson Thieme speaks, and Srijit Seal and Isaac Wilks speak in two symposia.
OpenTox Virtual Conference 2026, online
Srijit Seal speaks on assessing mutagenic impurities for ICH M7 with AI agents.
Society of Toxicology 66th Annual Meeting, San Antonio
Srijit Seal co-chairs a continuing education course with Kiara Fairman of FDA NCTR and speaks in a scientific session on AI in chemical risk assessment.
CropLife America 2026 Annual Meeting, Dallas
Isaac Wilks spoke on the panel "AI Advancing Discovery."
PCRM Summer Immersion on Innovative Approaches in Science, Baltimore
Srijit Seal spoke on AI agents in biology.
OpenADMET webinar, online
Srijit Seal spoke on making machine learning successful in drug discovery.
Watch the recording ↗
